Form D · Biotechnology
Lyra Therapeutics, Inc.
Watertown, MA · CIK 0001327273
Offering snapshot reported Jun 9, 2023 · SEC filing
- Reported sold
- $50M Offering amount: $50M
- Investors reported
- 24 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 25, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 9, 2023 | Initial | $50,000,008 | No comparison | 24 | SEC filing |
| Apr 26, 2022 | Initial | $100,494,970 | No comparison | 34 | SEC filing |
| Jan 27, 2020 | Initial | $28,049,999 | No comparison | 14 | SEC filing |
| Nov 28, 2016 | Initial | $5,999,999 | No comparison | 9 | SEC filing |
| Apr 12, 2013 | Initial | $17,956,999 | No comparison | 11 | SEC filing |
| Oct 30, 2012 | Initial | $5,078,139 | No comparison | 10 | SEC filing |
| Nov 8, 2011 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
| Sep 8, 2011 | Initial | $12,000,000 | No comparison | 10 | SEC filing |
| Aug 12, 2010 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
| May 18, 2010 | Initial | $10,051,308 | No comparison | 11 | SEC filing |
| Mar 19, 2010 | Initial | $1,000,000 | No comparison | 8 | SEC filing |
| Jan 20, 2010 | Initial | $2,050,000 | No comparison | 9 | SEC filing |
| Apr 14, 2009 | Initial | $8,187,500 | No comparison | Not reported | SEC filing |
| Feb 27, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Sep 24, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Apr 14, 2006 | Paper | Not reported | No comparison | Not reported | |
| Mar 28, 2006 | Paper | Not reported | No comparison | Not reported | |
| May 9, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $3.1M
- Finders' fees
- $0
- Form D file number
- 021-483903
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Cantor Fitzgerald & Co. | 134 | |
| William Blair & Company, L.L.C. | 1252 | |
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed Jun 9, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Altman | Director |
| Edward Anderson | Director |
| John Bishop, Ph.D. | Executive |
| Jason Cavalier | Executive |
| Earl M. Collier, Jr. | Director, Executive |
| Dennis Dougherty | Director |
| Don Elsey | Executive |
| James Goldstein | Director |
| Robert Langer | Director |
| Terrance Mc Guire | Director |
| Ann Merrifield | Director |
| C. Ann Merrifield | Director |
| Richard Mott | Director |
| Guido Neels | Director |
| Pamela Nelson | Executive |
| Richard Nieman, M.D. | Executive |
| Corinne Noyes | Executive |
| Maria Palasis | Director, Executive |
| Maria Palasis, Ph.D. | Director, Executive |
| Konstantin Poukalov | Director |
| R. Scott Rader | Director, Executive |
| Robert Richard, Ph.D. | Executive |
| Carmichael S. Roberts | Director |
| James Rosen | Director |
| Tony Semedo | Director |
| Bradford Smith | Director |
| W. Bradford Smith | Director |
| Nancy Snyderman, M.D., Facs | Director |
| James R. Tobin | Director |
| Harlan Waksal, M.D. | Director, Executive |
| George Whitesides | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
480 Arsenal Way
Watertown, MA, 02472
Watertown, MA, 02472